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Postural orthostatic tachycardia syndrome (POTS) is deﬁned as the development of
orthostatic symptoms associated with a rapid (within 10 minutes) increase in heart rate by
more than 30 beats per minute or to a heart rate that exceeds 120 beats per minute without
orthostatic hypotension. The symptoms of orthostatic intolerance are due to brain
hypoperfusion and sympathetic overaction. Patients are usually female and aged 15 to 50
years. POTS represents a category of disease rather than a single distinct illness. Patients with
POTS can experience diﬃculty with daily routines including housework, shopping, eating,
and attending work or school. Reports of patients with ‘‘POTS-like symptoms’’ have been
made for over 100 years.
The pathophysiologic mechanisms of POTS include peripheral denervation, -receptor
supersensitivity, hypovolemia and impaired cerebral autoregulation. Prolonged decondition-
ing may also interact with these mechanisms to exacerbate symptoms. Although 3 types of
POTS (low-ﬂow, normal-ﬂow, and high-ﬂow POTS) have been distinguished based on
diﬀerences in peripheral blood ﬂow and peripheral arterial resistance, thoracic hypovolemia is
the common ﬁnal pathophysiologic mechanism.
Therapies are directed at relieving the central hypovolemia or at compensating for the
circulatory dysfunctions. Treatments include use of water, saline infusion, -agonists, -
antagonists, and other agents that may correct the central hypovolemia. These have resulted in
varying degrees of success, and they are often used in combination.
(J Arrhythmia 2011; 27: 289–306)
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Introduction
Postural orthostatic tachycardia syndrome (POTS)
is a syndrome of orthostatic intolerance (OI) char-
acterized by excessive tachycardia and cerebral
hypoperfusion in the upright position.1–3) POTS is
deﬁned as a sustained heart rate increase of 30 bpm
or up to 120 bpm within the ﬁrst 10min of
orthostasis associated with symptoms of OI but
without signiﬁcant orthostatic hypotension (OH).
Its symptoms include palpitation, dizziness, light-
headedness, and syncope.1–3) Patients with POTS
are predominately female and relatively young,4,5)
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but can range in age from 15 to 50 years. There are
no detailed epidemiological studies, but millions of
people might be aﬀected by POTS in the USA.6)
Possible pathophysiological mechanisms of POTS
include peripheral denervation, venous pooling,
hypersensitivity of -adrenergic receptor,7) hypovol-
emia,8) and brain stem dysregulation.9) A wide range
of pharmacological treatments for POTS has been
attempted: for example, ﬂudrocortisones have been
used to increase intravascular volume, -agonists
such as midodrine have been used to induce
peripheral vasoconstriction, and -blockers or ivab-
radine (a selective inhibitor of If current) have been
used to suppress heart rate.10) This article reviews
pathophysiology, diagnosis, and management of
POTS.
History and background
By the mid-19th century, physicians had noticed
patients who were aﬄicted with a condition charac-
terized by extreme fatigue and signiﬁcantly reduced
exercise tolerance that seemed to occur suddenly
without obvious causes. During the American Civil
War, terms like ‘‘irritable heart syndrome’’ and
‘‘soldier’s heart’’ were used by DaCosta,11) who ﬁrst
drew attention to patients’ complaints of tachycardia
and palpitation. By the time of the World War I, a
series of reports had come out on similar conditions
that were called by a variety of names including
‘‘vasoregulatory asthenia’’ and ‘‘neurocirculatory
asthenia.’’ These reports postulated that aﬀected
patients had some sorts of functional cardiac
abnormality due to poor neural regulation of periph-
eral blood ﬂow.12) Around the time of the World War
II, MacLean et al.13) described a group of patients
who exhibited orthostatic tachycardia associated
with only a modest fall in blood pressure or who
suﬀered from exercise intolerance, palpitation, light-
headedness, and generalized weakness. They postu-
lated that the mechanism responsible for these
complaints might be a reduction in venous return
to the heart due to an impairment at the capillary
venous level.
In the 1960s, Frolich et al.14) published a report on
two patients who had developed pronounced postural
tachycardia with palpitation, anxiety, dizziness, and
near syncope. Both patients exhibited an exaggerated
response to intravenous isoproterenol and -block-
ade reduced symptoms. In 1982, Rosen and Cryer15)
used the term ‘‘postural tachycardia syndrome’’ in
reference to a patient who displayed a rise in heart
rate >44 bpm upon standing (without hypotension)
and also complained of postural palpitations, fatigue,
and exercise intolerance. Fouad et al.8) labeled this
disorder ‘‘idiopathic hypovolemia,’’ based on the role
of hypovolemia in postural tachycardia. In a more
contemporary study by Streeten, patients having
‘‘postural tachycardia’’ were shown to have marked
venous pooling of sodium pertechnetate Tc99 when
standing as well as an exaggerated response to
infusion of isoproterenol.16,17) Hoeldtke et al. sub-
sequently described a cohort of patients, all of whom
exhibited symptoms of postural tachycardia along
with exercise intolerance, anxiety, and cognitive
impairment.18,19)
In 1993, Schondorf and Low20) performed an
extensive analysis of 16 patients with profound
exercise intolerance, severe fatigue, lightheadedness,
and bowel hypomotility. During head-up tilt table
testing, these patients exhibited markedly abnormal
cardiovascular responses with a dramatic rise in
heart rates to as much as 120–170 bpm, often within
the ﬁrst 2–5 minutes of upright tilt. In 1995, they
operationally deﬁned the term ‘‘postural tachycardia
syndrome’’ as an increase in heart rate by more than
30 bpm or to more than 120 bpm within 10 minutes
of changing from a supine to an upright position
without associated hypotension.20) Grubb et al.21)
subsequently reported on a total of 28 patients with
these symptoms. During head-up tilt table testing,
each patient demonstrated a minimum increase in
heart rate 30 bpm during the ﬁrst 10 minutes of
upright posture. The peak heart rate exceeded
120 bpm within the ﬁrst 10 minutes of upright tilt
in almost all cases.
As is often the case in disorders that remain
unclariﬁed, many names have been used to describe
this syndrome (Table 1). Many investigators have
used the term ‘‘postural orthostatic tachycardia
syndrome (POTS)’’ to describe this constellation of
Table 1 Syndromes characterized by orthostatic intolerance
(Adopted from Ref. 28)
 Idiopathic orthostatic intolerance
 Postural tachycardia syndrome (POTS)
 Orthostatic tachycardia syndrome
 Sympathotonic orthostatic hypotension
 Hyperadrenergic orthostatic hypotension
 Hyperdynamic -adrenergic state
 Idiopathic hypovolemia
 Mitral valve prolapse syndrome
 Solider’s heart
 Vasoregulatory asthenia
 Irritable heart
 Orthostatic anemia
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signs and symptoms, and have felt that it represents
a mild (yet signiﬁcant) disturbance in autonomic
nervous system function (i.e., dysautonomia).3,20)
Epidemiology
The prevalence of POTS is unknown. In clinical
practice, it is probably about 5–10 times as common
as OH. One estimate of the prevalence was at least
170/100,00022) based on the investigators’ docu-
mentation that 40% of patients with chronic fatigue
syndrome have POTS. Robertson et al.23) have
reported that approximately 500,000 Americans
may suﬀer from some forms of POTS or OI. If this
prevalence is employed, there could be over 200,000
Japanese suﬀering from POTS. Approximately 75%
to 80% of POTS patients are female and between
15 and 50 years old;24) therefore, the typical POTS
patient is somewhere between menarche and men-
opause. POTS is relatively uncommon in preadoles-
cent children and may have a diﬀerent pathophysi-
ology in the very young. The reasons for its female
predominance are unclear, although women are
known to be more vulnerable to orthostatic stress.25)
Associations with the menstrual cycle or with altered
estrogen or progestin levels are yet to be established,
though some female patients report an increase of
symptoms in the premenstrual phase.26) The illness
may follow a remitting and relapsing clinical course,
often enduring for years, but seems in many
instances to be self-limited. Pregnancy may resolve
abnormalities.6) As currently construed, POTS was
ﬁrst reported in adults,3,20,23,27,28) but pediatric cases
have shown that POTS is a common form of OI
during upright tilt in adolescents with chronic fatigue
syndrome (CFS).29,30) In adults with CFS, approx-
imately 25% of patients exhibit typical signs of
POTS.31)
Diagnosis
POTS is presently deﬁned as the development of
OI symptoms accompanied by a heart rate increase
of at least 30 bpm or to a rate >120 beats/min
occurring within the ﬁrst 10 minutes of standing or
head-up tilt and in the absence of other chronic
debilitating disorders, prolonged bed rest, or medi-
cations that impair autonomic reﬂexes (Tables 2 and
3).3,28,32) Low et al.33) stated, with regard to the
typical age range of POTS patients (15–50 years),
that an increase of 30 beats/min exceeds the 99th
percentile for control subjects from 10 to 13 years of
age.
Most investigators focused on postural tachycar-
dia as an excessive increase in heart rate, represent-
ing the earliest, most consistent, and most easily
measurable ﬁnding of OI. It is important to realize,
however, that most patients with OI do not have OH
(a decrease in blood pressure of >20=10mmHg).
Rather, most of these patients exhibit only a modest
or no decrease in blood pressure, or even an increase
in blood pressure when they assume an upright
posture.28) Nevertheless, focusing only on heart rate
has the drawback of overlooking nonorthostatic
autonomic symptoms such as paroxysmal disturban-
ces in sweating, blood pressure regulation, thermo-
regulation, and bowel function.34)
Clinical features
The orthostatic symptoms in patients with POTS
consist of symptoms of reduced cerebral perfusion
coupled with those of sympathetic activation. The
most common symptoms are lightheadedness, palpi-
tation, symptoms of presyncope, tremulousness, and
weakness or heaviness (especially of the legs). These
Table 2 Criteria for POTS (Adopted from Ref. 3)
 Heart rate increment 30 bpm within 5min of standing or tilt-up
 Heart rate 120bpm within 5min of standing or tilt-up
 Orthostatic symptoms consistently develop
bpm: beats-per-minute
Table 3 Criteria of idiopathic orthostatic intolerance (OI) (Adopted from Ref. 28)
 Long-standing (6 months) and disabling orthostatic symptoms.
 Orthostatic tachycardia (30 bpm increase of heart rate on standing).
 Absence of an underlying cause (debilitating disease, substantial weight loss, prolonged
bed rest, peripheral neuropathy, medications that impair autonomic reﬂexes).
 Upright plasma norepinephrine 600 pg/ml
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symptoms are commonly exacerbated by heat and
exercise (Table 4).4) Other common symptoms are
shortness of breath and chest pain. Unlike patients
with OH, patients with POTS experience signiﬁcant
symptoms of sympathetic activation.35) Patients
often complain of headaches beginning in the
occipital region and radiating to the shoulders. There
may be an overrepresentation of migraine, sleep
disorders, and fatigue, and ﬁbromyalgia is some-
times associated.3) There is a clear overrepresenta-
tion of women.4)
Previous studies have indicated that central hypo-
volemia while upright is a consistent feature in
patients with POTS (Figure 1).36,37) Therefore, any
conditions associated with central hypovolemia that
may cause tachycardia (dehydration, anemia, or
hyperthyroidism) may also mimic POTS.37)
In addition to the tachycardia and OI, a striking
physical feature of POTS is the peripheral acrocya-
nosis that occurs in 40–50% of patients with POTS.5)
These patients experience a dark red-blue discolor-
ation of their legs, which are also cold to the touch.
This can extend from the feet to above the level of
the knees. Although this appearance is often called
venous pooling, the evidence does not support
excessive venous capacitance or an enhanced accu-
mulation of venous blood within the vasculature.
Instead, the available data indicate decreased overall
blood ﬂow in the aﬀected extremities, which results
in a relative coolness of the limbs and a type of
‘‘stagnant hypoxia.’’38,39) This may be mediated by a
deﬁcit of locally produced nitric oxide and is not
likely the result of increased pooling in venous
capacitance vessels.4)
Early studies suggested that approximately half of
patients were presumed to have viral illness,3,20)
although recent experience suggests that this is less
common. Other precipitating events include preg-
nancy, immunization, sepsis, surgery, and trauma.33)
A feature of POTS induced by a precipitating event
is the cyclic nature of symptoms. Some females will
have marked deterioration of their symptoms at
certain stages of their menstrual cycles, associated
with signiﬁcant weight and ﬂuid changes. Typically,
these patients have large ﬂuctuations in their
weights, sometimes up to 5 pounds.40)
Fatigue is commonly present.4) Patients complain
of poor exercise tolerance with physiological symp-
toms including reduced stroke volume and reﬂex
tachycardia; these symptoms are typical of subjects
who are deconditioned, such as persons who have
undergone prolonged bed rest.40) Along with poor
exercise tolerance, an excessively long recovery
cycle following exercise is often described. Addi-
tionally, patients typically note that they have low
energy levels, even at rest. A sense of fatigue will
sometimes occur in cycles, lasting for days or even
weeks and then receding.40)
Pathophysiology
POTS is a clinical manifestation of multiple
underlying mechanisms. It can be divided into a
number of overlapping pathophysiological models as
follows (Table 5).
Neuropathic POTS
About half of patients with POTS have a restricted
autonomic neuropathy with a length-dependent dis-
Table 4 Orthostatic and nonorthostatic symptoms in
patients with postural orthostatic tachycardia syndrome
(Adopted from Ref. 4)
Symptoms No. (%) of patients(N ¼ 152)
Orthostatic
Light-headedness or dizziness 118 (77.6)
Presyncope 92 (60.5)
Weakness 76 (50.0)
Palpitations 114 (75.0)
Tremulousness 57 (37.5)
Shortness of breath 42 (27.6)
Chest pain 37 (24.3)
Loss of sweating 8 (5.3)
Hyperhidrosis 14 (9.2)
Exacerbation by heat 81 (53.3)
Exacerbation by exercise 81 (53.3)
Exacerbation by meals 36 (23.7)
Exacerbation associated
with menses 22 (14.5)
Nonorthostatic
Bloating 36 (23.7)
Nausea 59 (38.8)
Vomiting 13 (8.6)
Abdominal pain 23 (15.1)
Constipation 23 (15.1)
Diarrhea 27 (17.8)
Bladder dysfunction 14 (9.2)
Pupillary dysfunction 5 (3.3)
Generalized associated
Fatigue 73 (48.0)
Sleep disturbance 48 (31.6)
Migraine headache 42 (27.6)
Myofascial pain 24 (15.8)
Neuropathic pain 3 (2.0)
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tribution of neuropathy (Figure 2).4,20,41) The term
length-dependent neuropathy refers to neuropathy in
which the ends of longer ﬁbers are aﬀected before
those of shorter ones. The evidence in support of
this is as follows. 1) Distal anhidrosis of the legs is
commonly found in thermoregulatory sweat testing
and quantitative sudomotor axon reﬂex testing (up to
50% of POTS patients).4,20,41) 2) Ganglionic acetyl-
choline receptor antibody is positive in 10–15% of
cases.4,42) 3) There is a blunted increase in post-
ganglionic sympathetic nerve discharge (muscle
sympathetic nerve activity).27) This peripheral ab-
normality might reﬂect partial dysautonomia. Astro-
nauts returning from prolonged exposure to micro-
gravity often display a form of OI with features
similar to POTS.43) This is believed to be due to
abnormal muscle sympathetic nerve activity.44) 4)
Leg arteriolar vasoconstriction is impaired. There-
fore, increased arterial inﬂow can enhance venous
ﬁlling and cause venous pooling, despite the fact that
venous capacitance is normal.39) 5) The increase in
norepinephrine spillover in the legs during ortho-
stasis is smaller in POTS patients than in normal
controls.45) 6) Excessive leg vein constriction is
observed in response to phenylephrine and NA
infusion, consistent with denervation hypersensitiv-
ity.17)
Hyperadrenergic POTS
One subset of POTS is characterized by an
excessive increase in plasma norepinephrine and
an increase in BP on standing (Figure 2).46,47) These
patients seem to manifest a form of -adrenergic
receptor hypersensitivity, a disorder referred to as
hyperadrenergic POTS.28) They tend to have prom-
Table 5 Proposed pathophysiological mechanisms of POTS
 Neuropathic
 Hyperadrenergic
 Genetic (Norepinephrine transfer protein deﬁciency)
 Hypovolemic
 Impaired cerebral autoregulation
 Histamine-related
 Deconditioning
 Regional blood volume and vascular properties
(Low ﬂow, normal ﬂow and high ﬂow POTS)
 Muscle pump defects
Figure 1 Proposed model of the pathophy-
siological and physiological mechanisms
leading to postural tachycardia and orthostat-
ic intolerance. (Adopted from Ref. 36)
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inent symptoms of sympathetic activation,47) such as
palpitation, anxiety, tachycardia, and tremulousness.
Over half of these patients will suﬀer from true
migraine headaches that include a deﬁnite prodrome
and unilateral (often frontal) onset with photophobia
and nausea.27) Many of these patients will display
orthostatic hypertension during standing or tilt and
an exaggerated response to low-dose isoproterenol
infusions while supine (Figure 3).7,48) It is unclear
whether this hypersensitivity is primary in the nature
of the condition or a manifestation of denervation
sensitivity.49) These patients exhibit a larger decrease
in BP following ganglionic blockade with trimetha-
phan, and higher upright plasma norepinephrine
levels, compared to nonhyperadrenergic POTS pa-
tients,47) presumably indicating a major role of
orthostatic sympathetic activation. Elevation of
plasma norepinephrine (600 pg/mL) was docu-
mented in 29.0% of patients tested in a recent
study.4)
Genetic
Recently, norepinephrine transporter (NET) pro-
tein deﬁciency has been shown to produce a complex
form of POTS in a single family. A single point
mutation in the NET protein50) exerts both central
and peripheral eﬀects on vascular regulation.51)
Despite its rarity, the illness has furnished an ideal
monogenetic model for autonomic illness, and
appropriate animal knockout models have been
Figure 2 Examples of blood pressure (BP) and heart rate recordings from a normal subject (top panel), a
patient with neuropathic POTS (middle panel), and a patient with hyperadrenergic POTS (bottom panel).
Note the modest reduction in BP in neuropathic POTS. Hyperadrenergic POTS is associated with prominent BP
oscillations, an orthostatic increment in systolic BP, and a prominent norepinephrine response to head-up tilt.
(Adopted from Ref. 41)
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constructed and investigated.52) NET-deﬁcient mice
have near-normal resting arterial pressure and heart
rate, likely resulting from increased sympathoinhi-
bition. When engaged in wakeful activities, how-
ever, these mice exhibited excessive tachycardia and
elevated blood pressure.53)
Hypovolemic
Absolute hypovolemia and low red blood cell
volume can occur in POTS patients and aggravate
symptoms of OI.4,54) Relative hypovolemia can
occur due to venous pooling and capillary leakage.55)
Associated with this propensity to hypovolemia in
POTS is an abnormal physiological response to
volume depletion. For example, POTS patients lack
the normal association between hypovolemia and
elevated standing norepinephrine levels.4) The renin-
angiotensin-aldosterone system plays a major role in
the neurohumoral maintenance of plasma volume.
In normal subjects, hypovolemia stimulates renin,
leading to a subsequent increase in angiotensin II
and aldosterone levels. These promote vasoconstric-
tion, and renal sodium and water retention. Low
renin and aldosterone levels were found in hypo-
volemic patients with OI and POTS, although the
opposite had been expected.54,56) These conditions
might contribute to impaired sodium retention and
hypovolemia. The sympathetic nervous system is a
determinant of renal renin release; therefore, partial
renal sympathetic denervation could explain low
renin levels.
Impaired cerebral autoregulation
POTS patients are found to have an excessive
decrease in cerebral blood ﬂow velocity during head-
up tilt. It is controversial as to whether this decrease
is due to an excessive sympathetic outﬂow to the
cerebral vasculature or to hyperventilation.9,57) It is
likely that these two factors interact, and that POTS
is caused by their combination.
Histamine-related
Some patients with POTS have episodic ﬂushing
and increased urinary levels of methylhistamine,
a primary urinary metabolite of histamine. These
patients are thought to have a coexisting mast cell
activation disorder that is associated with shortness
of breath, headache, lightheadedness, diarrhea, nau-
sea, and vomiting.58) Patients can experience a
hyperadrenergic response resulting in orthostatic
tachycardia and hypertension. At the present time,
it is unclear whether mast cell activation-associated
release of vasoactive mediators is the primary event
or if sympathetic activation results in mast cell
activation (Figure 4).58,59) In these patients, although
-adrenergic antagonists may exacerbate symptoms,
treatment with antihistamines (H1 and H2 antago-
nists) in combination with nonsteroidal anti-inﬂam-
matory drugs may be beneﬁcial.
Deconditioning
POTS patients have poor exercise tolerance, and
deconditioning is often present, especially in patients
Figure 3 Heart rate (A) and plasma cyclic AMP (cAMP) (B) responses to low-dose isoproterenol (ISP) infusion in the supine
position.
(A) Before isoproterenol infusion, there is no signiﬁcant diﬀerence in heart rate between postural orthostatic tachycardia syndrome (POTS)
patients and control subjects. After isoproterenol infusion, the heart rate of POTS patients increases signiﬁcantly compared with that of
control subjects (p < 0:01). (B) Before isoproterenol infusion, there is no signiﬁcant diﬀerence of the plasma cAMP concentration
between POTS patients and control subjects. After isoproterenol infusion, the plasma cAMP concentration increases signiﬁcantly in POTS
patients compared with that in control subjects (p < 0:05). (Adopted from Ref. 7)
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with prominent fatigue and ﬁbromyalgia-type symp-
toms.40) Masuki et al.41) have suggested that,
although anxiety is commonly present in POTS,
the HR response to orthostatic stress in POTS
patients is not caused by anxiety, but is rather a
physiological response that maintains arterial pres-
sure during venous pooling. These authors studied 13
patients with mild POTS and 10 matched controls.
In POTS patients, exercise was associated with a
greater HR elevation, especially while upright,
which was secondary to reduced stroke volume and
associated with poor exercise tolerance.60)
Both lower body negative pressure and exercise
ﬁndings seem remarkably similar to models of pure
deconditioning and bed rest. These ﬁndings in
combination with the ‘‘somatic hypervigilance’’
noted above raise the possibility that, in at least
some POTS patients, some event or illness initially
evoked orthostatic symptoms which were then
‘‘over-interpreted,’’ leading to reduced physical
activity and deconditioning. In this context, the
residual symptoms of POTS may have a strong
deconditioning component in at least some pa-
tients.40)
Regional blood volume and vascular properties
The distribution and disposition of gravitationally
displaced blood is controlled by many factors, chief
among them being regional blood ﬂow and vascular
compliance, and peripheral arterial and peripheral
venous resistance. The relative functionality of these
factors can provide a useful and physiologically
important means to further categorize patients with
POTS. Stewart et al.61–63) described 3 groups of
patients with POTS (Figures 5 and 6) based on
diﬀerences in peripheral blood ﬂow and peripheral
arterial resistance:
1. A low-blood-ﬂow, high-arterial-resistance,
high-peripheral-venous-resistance group (‘‘low-
ﬂow’’ POTS), characterized by pallor and
generally decreased blood ﬂow most notable
in the dependent parts of the body. This low-
ﬂow condition is related to defects in local
blood ﬂow regulation and mild absolute hypo-
volemia.
2. A normal-blood-ﬂow, normal-arterial-resist-
ance, normal-peripheral-venous-resistance
group (‘‘normal-ﬂow’’ POTS), characterized
by a normal supine phenotype with normal
peripheral resistance in the supine position but
enhanced peripheral resistance in the upright
position. This group exhibits speciﬁc venous
pooling within the splanchnic vascular bed,
making this a redistributive form of hypovol-
emia.
3. A high-blood-ﬂow, low-arterial-resistance, nor-
mal- to decreased-peripheral-venous-resistance
group (‘‘high-ﬂow’’ POTS), related to a long
tract neuropathy and characterized by high
cardiac output caused by inadequate peripheral
vasoconstriction in the supine and upright
positions. Patients typically are acyanotic and
warm to the touch, with extensive ﬁltration
resulting in dependent edema.
Low-ﬂow POTS
Low-ﬂow POTS patients are intensely peripher-
ally vasoconstricted while supine and have decreased
Figure 4 Proposed pathophysiological
mechanisms underlying the association be-
tween mast cell activation (MCA) and hyper-
adrenergic orthostatic intolerance. (Adopted
from Ref. 58)
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blood volume, increased total peripheral resistance,
and low resting cardiac output. They have a
characteristic phenotype of pallor, extensive supine
and upright acrocyanosis, cool skin and extremities,
and defective skeletal muscle pump.61,65) They are
usually tachycardic while supine, more so during
orthostasis. Hyperemic blood ﬂow, a measure of
endothelial cell function, is abnormal compared with
either control patients or patients with other subtypes
of POTS, indicating abnormal local blood ﬂow
regulation in these patients. Medow et al.66) have
recently shown that abnormalities in the regulation
Figure 5 Frequency distribution of peripheral blood ﬂow in patients with postural tachycardia syndrome (POTS) with high
venous pressure (Pv; middle) and normal Pv (bottom) compared with control subjects (top).
There is signiﬁcantly decreased blood ﬂow in POTS patients with high Pv (middle right) compared with control by 	2 and signiﬁcantly
increased leg blood ﬂow in normal-Pv POTS patients (bottom left and bottom right) compared with control subjects. However, bottom
data are bimodal, containing patients with normal blood ﬂow and patients with increased blood ﬂow. There appear to be (at least) 2
populations of POTS patients with normal Pv distinguished by blood ﬂow and peripheral arterial resistance. (Adopted from Ref. 61)
Mizumaki K Diagnosis and management of POTS
297
of cutaneous blood ﬂow are related to impairment
of NO release in patients with low-ﬂow POTS
(Figure 7). Another report has shown that the
frequencies of two polymorphisms that encode for
endothelial NO synthase (eNOS) are signiﬁcantly
lower in patients with POTS than in controls.67) This
genotype may inﬂuence the development of POTS
and the severity of POTS symptoms. It has been
reported thoracic hypovolemia may be a result of
increased angiotensin II, decreased renin, and rela-
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Figure 6 Changes in thoracic, splanchnic, pelvic, and leg percent volume changes during upright tilt averaged
over subject groups.
Splanchnic changes dominate normal (Nl)-ﬂow POTS. Low-ﬂow POTS patients have widespread blood collection.
High-ﬂow POTS patients have blood pooling in the dependent body parts. (Adopted from Ref. 61)
Figure 7
Left: Saline or, N!-nitro-L-arginine methyl ester hydrochloride (L-NAME; NO synthase inhibitor) administered to a representative
reference subject by iontophoresis followed by local heating to 43 C. An initial peak occurs and is followed by a higher plateau after
saline administration. Iontophoretic administration of L-NAME slightly blunts the initial peak and markedly decreases the plateau phase.
Right: Local heating followed by saline or L-NAME in a representative low-ﬂow POTS patient. The initial peak is present, but there is
marked attenuation of the NO-dependent plateau, even after saline administration, which resembles blunting by the NO inhibitor L-
NAME. Iontophoretic administration of L-NAME minimally blunts the initial peak but has no additional eﬀect on the plateau phase
because of preexistent impairment of NO release. (Adopted from Ref. 66)
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tive hypovolemia in patients with low-ﬂow POTS.62)
Although increased blood volume may eﬀectively
alleviate signs and symptoms, no improvement after
infusion of -blocker was demonstrated in patients
with low-ﬂow POTS.
Normal-ﬂow POTS
Some patients with POTS exhibit neither increas-
ed nor decreased recumbent blood ﬂow compared
with control subjects. These patients with so-called
‘‘normal-ﬂow POTS’’ make up an increasing subset
of identiﬁed patients. When supine, they appear
perfectly well; when upright, however, they develop
excessive tachycardia, greatly enhanced peripheral
vasoconstriction, and often acrocyanosis. There are
no ﬁndings suggesting a local peripheral defect.
Instead, their excessive vasoconstriction appears to
be related to thoracic hypovolemia and reciprocal
splanchnic pooling.63)
High-ﬂow POTS
Stewart et al.6,61) have indicated that patients
designated as having ‘‘high-ﬂow POTS’’ are periph-
erally vasodilated and mildly tachycardic when
supine and have relatively increased blood volume,
reduced total peripheral resistance, and high resting
cardiac output compared with healthy control sub-
jects. Support for a ‘‘long tract neuropathy’’ with
a neuropathic adrenergic vasoconstrictive defect
comes from Jacob et al.68) These patients exhibit
defective peripheral vasoconstriction during ortho-
stasis that leads to excess blood delivery to the lower
limbs, enhanced microvascular ﬁltration, and edema
formation. Acrocyanosis does not generally occur in
patients with this type of POTS. Persistent upright
vasodilation responds to vasoconstrictor therapy
with midodrine or similar agents. Patients are
extremely likely to develop illness after a viral
infection.37) A peripheral autoimmune neuropathy
may be involved; if so, it is self-limiting, although
its clinical course could extend for several months to
1 year or more.6)
Muscle pump defects
Physical forces comprise a primary defense
against the pooling of blood in the dependent lower
extremities in humans. This occurs through activity
of the ‘‘skeletal muscle pump’’ in which contractions
of leg and gluteal muscles increase interstitial
pressure and propel sequestered venous blood back
to the heart.69) Eﬀectiveness of this pumping action
is facilitated by the presence of one-way venous
valves. Patients whose venous valves are incompe-
tent or congenitally absent have severe OI.70)
Skeletal muscle may also be involved in neurogenic
compensation through chemoreceptors and local
control mechanisms.71) Recent data indicate that,
although most patients with POTS have a normal
muscle pump, the muscle pump is defective in
patients with low-ﬂow POTS who also have decreas-
ed resting peripheral blood ﬂow unrelated to exercise
capability but exacerbated by bed rest.65) Ambula-
tion is therefore essential for reduction of POTS
symptoms.
Treatment
Non-pharmacological
Treatment of POTS (Table 6) is diﬃcult because
no single therapy has been shown to be eﬀective, and
large-scale blinded studies have not been performed
yet.
Initially, any potentially reversible causes must
be identiﬁed; these may require their own special
treatment. Once a diagnosis has been established,
patients and their families must be educated as to the
nature of the disorder and necessity of avoiding any
aggravating factors like dehydration, extreme heat,
and consumption of alcohol. Increase in their ﬂuid
and sodium intake, and sleep with the heads of their
beds slightly elevated to help condition their bodies
to orthostatic stress are helpful to reduce symptom.
To reverse the eﬀects of hypovolemia, blood volume
Table 6 Summary of treatment options for POTS
Non-pharmacological
 Water and salt supplementation
 Exercise
 Elastic support hosiery
 Catheter ablation (sinus node modiﬁcation)

Pharmacological
 Fludrocortisone
 Desmopression (DDAVP)
 1-adrenoreceptor agonist (midodrine,
phenylephrine)
 -blockers (propranolol, esmolol)
 Central sympatholytic agents
(clonidine, methyldopa, phenobarbital)
 Pyridostigmine
 Ivabradine
 Octreotide
 Erythropoietin
 Selective serotonin reuptake inhibitors (SSRIs)
Selective norepinephrine reuptake inhibitors (SNRIs)
 Methylphenidate

The eﬃcacy of sinus node modiﬁcation for POTS remains
controversial.
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expansion can be achieved rapidly by infusion of
saline. Infusion of 1 L saline over 1 hour signiﬁ-
cantly reduces tachycardia in subjects with POTS.68)
The beneﬁcial eﬀects of saline infusion are some-
times delayed by a day or more. Although volume
expansion is eﬀective and provides relatively rapid
relief from symptoms, it is seldom a practical option
for regular, prolonged use, as the vascular access
required for this procedure is associated with risk
of infection. Major treatment modalities are listed in
Table 6.
Aerobic exercise and resistance training are also
beneﬁcial.72) Patients with POTS should therefore be
encouraged to slowly work up to doing aerobic
exercise for 20min 3 times per week.34) An exercise
program incorporating regular aerobic exercise and
lower limb resistance training may aid blood volume
expansion and reverse deconditioning. In a random-
ized controlled trial, endurance exercise training
(a 3-month jogging program, starting at 30min of
jogging per day, 3 days per week, and increasing the
duration by 10min each month up to 50min per day,
3 days per week) improved OI symptoms in POTS
patients.72) More recently, Fu et al.73) have reported
that short-term exercise training increased cardiac
size and mass and expanded blood and plasma
volume, and thus improved or even cured POTS
(Figure 8). This suggests that POTS per se is in fact
a consequence of deconditioning, and carefully
prescribed exercise training can be used as an
eﬀective nondrug therapy for POTS patients. Pa-
tients with signs of deconditioning may beneﬁt from
initial exercise training in a swimming pool. This
confers the beneﬁts of both buoyant support and
hydrostatic pressure-enhanced venous return. Exer-
cise has the added beneﬁt of increasing blood
volume, thereby diminishing hypovolemia-related
symptoms. Elastic support garments such as panty-
hose and Lycra bicycle shorts and leggings can also
minimize venous pooling and enhance venous
return. These are most useful if they can provide
30 to 40mmHg counterpressure.37)
Pharmacological
Fludrocortisone and desmopressin (DDAVP)
For long-term treatment of patients with hypovol-
emia, a mineral corticoid agent, ﬂudrocortisone, is
often used. It not only expands plasma volume but
also appears to sensitize peripheral -adrenergic
receptors to the patient’s own catecholamines.74)
Fludrocortisone, bisoprolol or both improved the
symptoms and lessened the hemodynamic abnor-
malities in patients with POTS.75) Side eﬀects
include hypokalemia and hypomagnesemia. Another
volume expanding agent that may be helpful is
Figure 8 Blood volume and left ventricular mass in POTS patients before and after 3 months of exercise
training and in controls.
Values are expressed as individuals and median (25th, 75th percentiles). 

p < 0:01 compared with before training in
the postural orthostatic tachycardia syndrome (POTS). yyp < 0:01 compared with controls. (Adopted from Ref. 73)
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desmopressin (an oral vasopressin analog), especial-
ly in patients who complain of nocturnal polyuria.
However, desmopressin may sometimes cause head-
aches and hyponatremia.34)
-1 adrenoreceptor agonist
Midodrine causes peripheral arterial and venous
constriction, and improved symptoms and sup-
pressed the heart rate response to tilting in patients
with POTS.76) In another similar study, midodrine
(10mg) suppressed the standing heart rate but did
not alter the standing time of nine POTS subjects.77)
Midodrine (5–10mg) reduced resting and upright
heart rate signiﬁcantly.68) It should be noted that all
of these studies were concerned with acute rather
than long-term POTS treatment. Intravenous phenyl-
ephrine improved OI and suppressed heart rate
increase when the subject was tilted to an angle of
35 degrees in patients with POTS.78) Using strain
gauge plethysmography, the same study showed that
phenylepherine causes signiﬁcant peripheral vaso-
constriction and venoconstriction. Side eﬀects in-
clude supine hypertension and piloerection.
-blockers
In patients with POTS, propranolol (single dose)
reduced the resting heart rate, and the immediate and
5min heart rate responses to tilt, though symptoms
did not improve.76) Long-term propranolol (10mg
daily) can be used successfully in the treatment
of POTS and to alleviate associated symptoms.79)
Esmolol, a -1 adrenergic antagonist (rapid onset
and a very short duration of action), did not improve
OI or hemodynamics in patients with POTS.78) Dose-
limiting side eﬀects include fatigue and postural
hypotension that could contribute to dizziness.
Central sympatholytic agents
Agents with central sympatholytic activity can be
helpful in the treatment of selected patients, but they
should be used carefully as some patients can be
quite sensitive to their eﬀects. Clonidine, an -2
agonist with a central sympatholytic eﬀect, has been
one of the most eﬀective agents against POTS.80)
Clonidine can stabilize heart rate and blood pressure
in patients with a high degree of postganglionic
sympathetic involvement and hypersensitive post-
junctional -2 receptors (which are abundant in the
venous system). Some groups have reported similar
success with methyldopa, while other groups have
suggested that phenobarbital may also be useful.28,33)
These agents may cause drowsiness, dry mouth, or
dizziness. Due to their eﬀects on blood pressure,
central sympatholytic agents should be reserved for
patients exhibiting hemodynamic and symptomatic
changes consistent with hyperadrenergic POTS.
Although they are often recommended as treatment
possibilities in expert reviews,28,33) only very limited
evidence supports such use; instead, their use should
be limited to patients with refractory symptoms on a
trial basis.
Pyridostigmine
The acetylcholinesterase inhibitor pyridostigmine
is used successfully to treat POTS.81) It achieves this
eﬀect by increasing the availability of acetylcholine
at both ganglionic nicotinic acetylcholine receptors
and postganglionic muscarinic acetylcholine recep-
tors. This results in increased parasympathetic tone,
increased cardiovagal tone, and decreased heart
rate.81) Procholinergic side eﬀects include diarrhea
and excess salivation.
Ivabradine
Ivabradine is a selective inhibitor of cardiac
pacemaker If current that contributes to sinus node
automaticity. This selectivity confers an ability to
reduce heart rate without aﬀecting inotropic or
dromotropic activity. Some investigators have sug-
gested that ivabradine could be used in the treatment
of POTS.82) We have also reported a POTS patient in
whom ivabradine signiﬁcantly reduced heart rate
upon standing and dramatically improved orthostatic
symptoms.83)
Octreotide
Octreotide, a somatostatin analog, produces sys-
temic vasoconstriction as well as selective splanch-
nic vasoconstriction, and is used for the treatment of
POTS, postprandial hypotension, and hypotension
associated with diabetic neuropathies.19) Its use is,
unfortunately, limited by side eﬀects that include
abdominal pain and diarrhea, and inconvenience of
subcutaneous administration. It is used successfully
in combination with midodrine hydrochloride, which
seems to potentiate its eﬀects.84)
Erythropoietin
Erythropoietin is a growth factor that stimulates
production of red blood cells in the bone marrow,
thereby increasing red blood cell mass and central
blood volume. Erythropoietin increases sensitivity to
angiotensin II with vasoconstrictive eﬀects.85,86) A
single observational study yielded little objective
evidence for eﬃcacy of erythropoietin against
POTS.87) Erythropoietin is occasionally suggested
for patients with refractory symptoms, where con-
servative or evidence-based approaches have failed.
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Selective serotonin reuptake inhibitors (SSRIs) and
selective norepinephrine reuptake inhibitors (SNRIs)
Eﬃcacy of SSRIs in preventing neurocardiogenic
syncope and OH has been demonstrated in a double-
blind, randomized, placebo controlled trial and in
various observational studies.88,89) Serotonin plays an
important role in central control of both heart rate and
blood pressure.90) Despite the fact that SSRIs have
been documented as a useful treatment option for
POTS, this is anecdotal and there is no experimental
evidence of their eﬃcacy in this context.
There are similar anecdotal descriptions, but no
evidence, of the eﬃcacy of venlafaxine, an SNRI.
Venlafaxine has cardiovascular side eﬀects includ-
ing tachycardia, palpitation, OH, and an increase in
mean arterial pressure.91) In healthy subjects, SNRIs
(reboxetine and sibutramine) reduce tilt-induced
syncope or pre-syncope and increase supine blood
pressure, but are associated with a signiﬁcant
increase in heart rate pre- and post-tilting.92,93)
Methylphenidate
Methylphenidate causes vasoconstriction by in-
creasing presynaptic catecholamine release, decreas-
ing reuptake, and inhibiting monoamine oxidase.
Methylphenidate is useful for treatment of vasovagal
syncope94) and suggested to reduce postural symp-
toms in POTS; however, there is no evidence for this.
Catheter ablation
The eﬃcacy of sinus node modiﬁcation in patients
with POTS remains controversial. Shen et al.95) have
reported that sinus rate was eﬀectively slowed by
sinus node modiﬁcation, but clinical symptoms did
not signiﬁcantly improve. Moreover, in some pa-
tients, sinus node modiﬁcation worsened the symp-
toms of cerebrovascular hypoperfusion because of
uncompensated central hypovolemia. In contrast,
Brady et al.96) reported that sinus node modiﬁcation
improved orthostatic symptoms in POTS patients
with a pathophysiology resembling inappropriate
sinus tachycardia. Because of the heterogeneous
etiologies of POTS patients, the eﬀects of sinus node
modiﬁcation could diﬀer greatly from patient to
patient.
Only limited data have been published regarding
the eﬃcacy of atrioventricular node ablation and
pacemaker implantation therapy in patients with
POTS. Shen et al.95) reported four patients with
POTS in whom atrioventricular node ablation and
pacemaker implantation were performed, yet in
whom most of the extracardiac symptoms remained
unrelieved. In contrast, we have recently reported a
patient with drug-refractory POTS in whom atrio-
ventricular node ablation and pacemaker implanta-
tion dramatically improved symptoms and elimi-
nated syncope.83) In our patient, sinus rate upon
standing was suppressed by the procedure, and heart
rate variability analyses revealed a decrease in the
ratio of low-frequency to high-frequency compo-
nents along with an increase in the high-frequency
component during a head-up tilt test, indicating
B
A
Figure 9 Heart rate trend from Holter monitoring in a 42-year-old woman with POTS.
Tachycardia responses to standing were frequently demonstrated before the atrioventricular node ablation (panel A).
Following the procedure, these responses were eﬀectively suppressed and heart rate seldom reached the upper tracking
rate of 120 bpm of the pacemaker (panel B). HR = heart rate. (Adopted from Ref. 83)
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postprocedural suppression of the patient’s excessive
sympathetic drive upon standing (Figures 9 and 10).
On the other hand, Kanjwal et al.97) have recently
reported a series of 6 patients who developed new-
onset POTS following successful slow pathway
ablation for atrioventricular nodal reentrant tachy-
cardia. Damage to the vagal ﬁbers supplying the
sinus and atrioventricular nodal area was suggested
as a possible mechanism for the onset of POTS.
Because cardiac adrenergic and cholinergic nerves
are closely juxtaposed,98) cholinergic and adrenergic
withdrawal could occur after ablation of the atrio-
ventricular nodal area, possibly depending on dif-
ferences in ablation procedures, e.g., sites and
amounts of application of radiofrequency energy.
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